Literature DB >> 18161676

Risk factors for the development of cephalic arch stenosis.

A Jaberi1, D Schwartz, R Marticorena, N Dacouris, V Prabhudesai, P McFarlane, S Donnelly.   

Abstract

PURPOSE: The creation of a vascular access is necessary in hemodialysis patients, including those with marginal vessels. Upper arm fistulae are attractive due to the ease of creation and of achieving high access flow rates. Cephalic arch stenosis (CAS) can lead to failure of upper arm fistulae and is increasingly identified. We hypothesized that CAS is promoted by high blood flow rates, brachiocephalic fistulae, and an angle of cephalic vein insertion approaching 90 degrees.
METHODS: All patients requiring a fistulogram between January 2004 and May 2006 had surveillance fluoroscopy of the central veins. Demographic, clinical and laboratory parameters were collected and the angle of the cephalic vein insertion measured by 3 blinded independent observers.
RESULTS: Fifty-eight patients had fistulograms and CAS was detected in 18 subjects. Significant differences between the CAS and non-CAS groups were brachiocephalic fistula site (p = 0.046), access flow (mL/min) (p = 0.012), and absence of diabetes (p = 0.03). Univariate predictors of CAS include access flow (per 100 mL/min) (p = 0.042), platelet count (p = 0.031) and calcium-phosphate product (p = 0.026). The relationship of brachiocephalic site and CAS was confounded by access flow [(per 100 mL/min)*brachiocephalic fistula site (p = 0.016)] and fistula age [brachiocephalic fistula site*fistula age (p = 0.017)]. In multivariate analysis, renovascular disease, calcium-phosphate product, platelet count and access flow (per 100 mL/min)*brachiocephalic fistula predicted CAS (p < 0.001, Negelkerke's R-Square = 0.55). The angle of insertion of the cephalic vein was not predictive for CAS.
CONCLUSIONS: CAS may be a long-term consequence of high blood flow rates. The interaction of access flow and brachiocephalic fistula supports the hypothesis that high flow through a brachiocephalic fistula promotes CAS. The multiple factors influencing cephalic arch remodeling require further research.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18161676

Source DB:  PubMed          Journal:  J Vasc Access        ISSN: 1129-7298            Impact factor:   2.283


  7 in total

1.  Restoration of wall shear stress in the cephalic vein during extreme hemodynamics.

Authors:  M E Boghosian; M S Hammes; K W Cassel; S M J Akherat; F Coe
Journal:  J Med Eng Technol       Date:  2019-04-03

2.  The geometry of arteriovenous fistulas using endothelial nitric oxide synthase mouse models.

Authors:  Isabelle Falzon; Hannah Northrup; Lingling Guo; John Totenhagen; Timmy Lee; Yan-Ting Shiu
Journal:  Kidney360       Date:  2020-09-24

3.  A Report of Two Cases of Hazards Associated with High Flow Arteriovenous Fistula in ESRD Patients.

Authors:  Vipuj Shah; Rakesh Navuluri; Yolanda Becker; Mary Hammes
Journal:  Case Rep Nephrol       Date:  2018-04-10

4.  Central Transposition of the Cephalic Vein in Patients with Brachiocephalic Arteriovenous Fistula and Cephalic Arch Stenosis.

Authors:  Jihoon Jang; Heekyung Jung; Jayun Cho; Jihye Kim; Hyung-Kee Kim; Seung Huh
Journal:  Vasc Specialist Int       Date:  2014-06-30

Review 5.  Hemodynamic and biologic determinates of arteriovenous fistula outcomes in renal failure patients.

Authors:  Mary Hammes
Journal:  Biomed Res Int       Date:  2015-10-01       Impact factor: 3.411

6.  Increased Inlet Blood Flow Velocity Predicts Low Wall Shear Stress in the Cephalic Arch of Patients with Brachiocephalic Fistula Access.

Authors:  Mary Hammes; Michael Boghosian; Kevin Cassel; Sydeaka Watson; Brian Funaki; Taral Doshi; S M Javid Mahmoudzadeh Akherat; Jane Hines; Fredric Coe
Journal:  PLoS One       Date:  2016-04-13       Impact factor: 3.240

7.  A Systematic Review and Meta-Analysis of Circulating Biomarkers Associated with Failure of Arteriovenous Fistulae for Haemodialysis.

Authors:  Susan K Morton; Alexander J Rodríguez; Dylan R Morris; Abhishta P Bhandari; Joseph V Moxon; Jonathan Golledge
Journal:  PLoS One       Date:  2016-07-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.